IMPORTANCE Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of immunotherapeutics, many of which are nonspecific. Even with current therapies, a subset of patients has medically refractory MG. The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however, the duration of these benefits after treatment is unclear.
achieved with acetylcholinesterase inhibitors; however, most patients require immunotherapy such as corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, plasma exchange, and intravenous immunoglobulin at some point in their disease course to achieve sustained clinical remission. [2] [3] [4] Thymectomy, regardless of the presence of a thymoma, is also considered a therapeutic option based on prior clinical experience; however, results and conclusions from the recently completed placebo-controlled thymectomy trial in nonthymomatous MG are pending at this time. 5 Despite these therapeutic options, a subset of patients has medically refractory MG or intolerable adverse effects from medication. 6 Autoreactive B cells have a clear pathogenic role in the development of MG, and B-cell-directed therapy has emerged as a highly effective tool in managing other autoimmune diseases such as rheumatoid arthritis and neuromyelitis optica. 7, 8 Several groups [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] have also observed the benefits of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with MG. In addition to significant clinical improvement, rituximab also allowed for tapering and subsequent discontinuation of other immunotherapies in patients with acetylcholine receptor autoantibody-positive (AChR+) and muscle-specific kinase autoantibody-positive MG. 9 However, the duration of clinical remission among patients treated with rituximab while not receiving other immunotherapy, especially considering the prior refractory nature of their disease, is unclear. The number of rituximab treatment cycles necessary to achieve long-term remission also remains unknown. Herein, we report our experience with the long-term effects of rituximab in 16 patients with refractory AChR+ MG who were followed up for 18 to 84 months, representing to our knowledge the longest follow-up of a single MG cohort to date.
Methods

Patients
This retrospective study included patients with generalized MG referred to the Yale Myasthenia Gravis Clinic, New Haven, Connecticut, from January 1, 2007, to December 31, 2015 . Sixteen patients with AChR+ refractory generalized disease and a minimum of 12 months of follow-up after completion of the initial set of rituximab treatment cycles were identified (Table) . This study was approved by the institutional review board of Yale University as part of an observational study examining the treatment and disease course of MG. All patients provided written informed consent. Disease was defined as refractory when the immunotherapy dosage could not be lowered without clinical relapse, inadequate clinical control of the disease was achieved during the immunotherapy regimen, or severe adverse effects due to current immunosuppressive therapy were present. Pretreatment and posttreatment immunotherapy regimens, clinical symptoms, and examination findings were evaluated. The Myasthenia Gravis Foundation of America (MGFA) clinical classification criteria 19 and postintervention status were used to assign clinical state a minimum of 12 months after completion of the initial set of rituximab cycles. The number of administered rituximab treatment cycles, time since the last treatment cycle, and times to relapse and postrelapse treatments were reviewed. In addition, anti-AChR antibody levels, measured by conventional radioimmunoassays (reference value, ≤0.02 nmol/L; Mayo Medical Laboratories), were assessed in patients before initiation of rituximab therapy, at the end of each cycle, at the time of clinical relapse, and at the last follow-up. Statistical analysis was performed using GraphPad Prism (GraphPad Software), and P values were calculated using nonparametric Friedman and Wilcoxon matched-pairs signed rank tests.
Rituximab
Because no established infusion protocol for rituximab use in MG currently exists, we used a standard protocol adopted from the non-Hodgkin lymphoma regimen of 4 weekly infusions of 375 mg/m 2 . One cycle is defined as 1 infusion per week for 4 consecutive weeks. The interval between cycles was 6 months. Infusions were completed per protocol in the outpatient infusion center at our institution. Our patients were treated with an initial 2-to 4-cycle regimen. The number of cycles was mainly based on reaching a symptom-free state and patient toleration of tapering or withdrawal of other immunotherapies (ie, corticosteroids). The number of rituximab treatment cycles or interval between cycles was not dictated by B-cell counts.
Conventional Immunotherapy
All prior immunotherapies were reviewed. These included prednisone, which is the standard first-line agent; plasma exchange; azathioprine; mycophenolate mofetil; and intravenous immunoglobulin.
Safety and Adverse Effects
In addition to clinical follow-up, we reviewed the infusion center notes and monitored complete blood cell counts and liver function test profiles to evaluate the safety profile. Periodic
Key Points
Question Is the rituximab response in treatment-refractory acetylcholine receptor autoantibody-positive myasthenia gravis (AChR+ MG) durable?
Findings In this case series study of 16 patients with AChR+ MG who were treated with rituximab and followed up for 18 to 84 months, all patients were observed to have clinical improvement. Nine patients had a relapse within a mean of 36 months after the last treatment cycle; the remaining 7 continued to maintain clinical benefit during a mean follow-up of 47 months.
Meaning Rituximab appears to be an effective option with sustained long-term benefit after treatment in patients with refractory AChR+ MG. a Refractory criteria include the following: (1) inability to lower immunotherapy without clinical relapse, (2) not clinically controlled with the immunotherapy regimen, and (3) severe adverse effects due to immunotherapy.
b Receiving Rtx for treatment of rheumatoid arthritis.
c The patient had an unplanned pregnancy during the second cycle of Rtx treatment. Treatment was discontinued. She had an uncomplicated pregnancy and delivery.
Serum Affinity Proteomics
Preinfusion and postinfusion serial blood samples were collected from 4 patients and 10 healthy control individuals after obtaining informed consent. Serum was obtained by centrifugation of whole-blood samples and was cryopreserved at −80°C. A fluorescent multiplexed magnetic bead-based screening assay (R&D Systems, Inc) was performed in accordance with the manufacturer's protocol for the following 10 cytokines: interleukin 4 (IL-4), IL-5, IL-6, IL-10, IL-17A, IL-17F, tumor necrosis factor, interferon γ, vascular endothelial growth factor, and resistin. The samples were analyzed in duplicate and diluted 2-fold. Results were expressed as a mean value in pictograms per milliliter. We used the Mann-Whitney test to determine statistical significance (P < .05).
Results
Of the 16 patients in the study (6 men and 10 women; median age, 42 [range, 18-69] years), 15 were receiving prednisone before initiating rituximab therapy (Table) . Eight patients were also receiving a corticosteroid-sparing agent (azathioprine in 6 and mycophenolate mofetil in 2 per liter, multiply by 0.001]) after the second cycle, but this resolved without intervention. Treatment had to be stopped in 1 patient owing to an unplanned pregnancy during the second cycle. She went on to have an uncomplicated pregnancy and delivery.
Nine of 16 patients (56%) experienced a relapse in a mean of 36 (range, 24-47) months after the last rituximab treatment cycle (Figure 1) . The 4 patients who had received 2 cycles had a relapse within a mean follow-up of 33 months. The 4 patients who had received 3 cycles had a relapse within a mean follow-up of 36 (range, 29-44) months. One patient received 4 cycles and had a relapse at 47 months. All of these patients improved again after further immunosuppression therapy (intravenous immunoglobulin or plasma exchange in 7; highdose prednisone in 1; and an additional cycle of rituximab in 4; some received more than 1 treatment for relapse). The MGFA postintervention status at their most recent follow-up was pharmacologic remission (n = 7) or MM-1 (MM with some form of immunotherapy for MG) (n = 2).
Seven of 16 patients (44%) remained clinically stable with follow-up ranging from 18 to 81 months (mean follow-up, 47 months) (Figure 1 ). The MGFA postintervention status at their most recent follow-up was complete stable remission (n = 5), pharmacologic remission (n = 1), or MM-0 (n = 1).
Because we observed a mean time to relapse of 36 months, we compared durability of benefit in patients followed up for more than 48 months (12 patients) and 48 months or less (4 patients) after completion of the initial treatment regimen. Of those patients with follow-up of more than 48 months, 8 of 12 patients had a relapse in a mean follow-up of 37 (range, 29-47) We also reviewed the time from diagnosis to initiation of first treatment with rituximab in our cohort, which was a mean of 36 (range, 9-90) months. The mean duration of disease before treatment in the relapse group was 31 (range, 9-61) months; in the nonrelapse group, 41 (range, 10-90) months (Figure 1) . We observed no difference in the time from diagnosis to initiation of rituximab therapy and response durability based on these data.
A total of 13 patients in our cohort had a thymectomy. Among the 6 patients who underwent thymectomy less than 12 months before starting treatment, 4 had a relapse in a mean time of 36 (range, 29-44) months. Among the 7 patients who underwent thymectomy more than 12 months before starting treatment, 4 had a relapse in a mean time of 35 (range, 24-47) months. The relapse rate was 67% in the group with thymectomy less than 12 months before rituximab treatment (mean, 6.2 months) and 57% in the group with thymectomy more than 12 months before rituximab treatment (mean, 34 months). The relapse rates appear similar between these 2 groups. Only 1 of 3 patients who did not undergo thymectomy had a relapse at 39 months. However, no firm conclusions can be drawn from such a small number of patients.
Anti-AChR Antibody Levels
The following statistically significant decreases in anti-AChR antibody levels was observed after treatment with the initial set of rituximab cycles ( Figure 2 ): 33% after cycle 1 (100% vs 67%; P = .004); 20% after cycle 2 (compared with cycle 1) (67% vs 47%; P = .008); and 17% after cycle 3 (compared with cycle 2) (47% vs 30%; P = .02). In the patients who did not have a relapse (eFigure 1A in the Supplement), a sustained decrease in anti-AChR antibody level was noted until their last follow-up (mean antibody level before rituximab treatment, 24.05 nmol/L; after last cycle, 10.8 nmol/L; and at last follow-up, 15 .65 nmol/L; P = .01). In the patients who had a relapse after initial cycles of rituximab treatment (eFigure 1B in the Supplement), no significant difference was noted in the anti-AChR antibody levels at relapse (mean antibody level after last cycle, 2.72 nmol/L; at the time of relapse, 2.87 nmol/L; P = .22). However, 1 patient had a dramatic rise in anti-AChR antibody level at the time of a second relapse that occurred in the setting of a new diagnosis of stage IV adenocarcinoma with an unknown primary site of origin.
Serum Cytokine Levels
Levels of 8 of the 10 cytokines measured (IL-4, IL-5, IL-6, IL-10, IL-17A, IL-17F, tumor necrosis factor, and interferon γ) were below the level of detection for the assay, implying that their levels in serum were not elevated. No statistically significant differences in serum levels of resistin and vascular endothelial growth factor were observed between healthy donor and patient serum samples before the initiation of rituximab treatment (eFigure 2 in the Supplement). We also found no appreciable change in the concentrations of resistin and vascular endothelial growth factor with rituximab treatment or after achieving a state of clinical remission, during longitudinal follow-up. One of the 4 patients studied experienced a relapse, but there was no significant difference observed in the levels of these 2 cytokines before and after relapse.
Discussion
The need for additional treatments, particularly for patients who do not respond to or have intolerable adverse effects from existing immunosuppressive therapy, has led to an interest in targeted immunotherapies. Rituximab is an appealing choice owing to its B-cell-targeting mechanism of action and the precedence for its use in the treatment of other autoimmune diseases, such as rheumatoid arthritis. 7, 20, 21 In this retrospective analysis of 16 patients with refractory AChR+ MG, rituximab appears to have a durable response. Our results support the hypothesis that rituximab can be helpful in managing refractory MG. These findings are in agreement with previous reports of its benefit. 9, 10, 22, 23 The number of rituximab treatment cycles necessary to achieve disease remission has been unclear. A minimum of 2 cycles appear to be needed, because most of the patients in our cohort required approximately 1 year to taper other therapies. As observed in previous studies, 10 some patients may need additional cycles. Although patients treated with more cycles tended to have a longer-lasting response, our sample size in each group is too small to draw any firm conclusions. To date, guidelines on when to discontinue or repeat rituximab treatment are yet to be established. As a practical matter, patients with evidence of clinical disease relapse and a minimum of 6 months since the last cycle should be considered for retreatment in the absence of medical contraindications. The relapse rate in our cohort was 56%, typically occurring about 3 years after the last rituximab treatment cycle. This relapse rate is similar to those of previously reported cohorts, 10 but after a longer duration of disease stability. After an induction regimen, a mean time to relapse of 17 (ranging, 6-34) months was observed in an independent study. 10 The patients with relapse in our cohort were able to achieve clinical improvement again after treatment with further immunosuppression. Thymectomy is certainly a possible confounder. Acknowledging the limitation of our sample size, thymectomy status, timing of thymectomy or pathologic findings in the thymus did not seem to influence disease relapse or durability of response in our cohort. Biomarkers would be very helpful in guiding clinicians as to whom to offer additional cycles. Anti-AChR antibody levels can be helpful in assessing the response to treatment because these levels were noted to decrease after the administration of rituximab. However, their role in predicting relapse is less clear because we did not note any significant increase in the levels at the time of relapse, although our small sample size limits definitive conclusion.
Our analysis of 10 cytokines that have been associated with the immunopathogenesis of MG 24,25 did not reveal any appreciable changes with B-cell depletion, clinical remission, or relapse. Acknowledging the limitation of sample size, further studies are needed to attribute value to these cytokines as biomarkers and to identify other indicators of disease activity and response to therapy. The effects of rituximab on B cells as well as putative T-cellmediated immune dysregulation in MG need further investigation. We plan to apply recently developed assays 26, 27 to the prospective clinical trial of rituximab in MG currently under way.
28
All patients followed up in this study tolerated rituximab with no severe hematologic derangements or infusion reactions. Although the most common adverse effect is an infusion reaction, progressive multifocal leukoencephalopathy is also of concern after rituximab therapy 29, 30 ; however, the relative risk is thought to be low. 31 A recent case report 32 has described the occurrence of progressive multifocal leukoencephalopathy in a patient with seronegative MG, having been treated with rituximab in addition to prednisone, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, and plasma exchange at different times during the course of disease. What role aggressive, long-term immunosuppression therapy had in this case is unclear. Nevertheless, clinical monitoring per best medical practice standards and minimizing combination immunosuppressive regimens is required and strongly advised when considering the initiation of rituximab therapy.
Conclusions
We found B-cell depletion therapy to be an effective option with sustained long-term benefit after treatment in patients with refractory AChR+ MG. This study represents, to our knowledge, one of the largest single-center studies with extended long-term follow-up. A prospective, placebo-controlled clinical trial is currently under way that will further help to evaluate the efficacy, safety, and pharmacodynamics of rituximab in MG. 28 Identification of markers of disease activity, responsiveness to therapy, clinical relapse, and remission are critical next steps in the development of evidence-based practice parameters for rituximab in the treatment of MG as well as other potential target therapeutics. 
